Benzinga··Vandana SinghBaxter Cancer Drug Supply Crisis Compounds Earnings Weakness
Baxter faces EU cancer drug shortage extending to Q1 2027 amid disappointing 2026 earnings guidance, projecting $1.85-$2.05 EPS versus $2.25 consensus.
BAXearnings guidancesupply chain